现有两种制剂:①罗格列酮(rosiglitazone):用量 为4~8mg/d,每日1次或分2次口服;②吡格列酮(pioglitazone):用量为15~30mg/d, 每日1次口服。
基于200个网页-相关网页
福辛普利和吡格利酮联合应用治疗Ⅱ型糖尿病高血压的临床观察-临床医学论文-中国论文联盟 关键词: 福辛普利; 吡格利酮; Ⅱ型糖尿病 [gap=1164]Key words: Fosinporil; Pioglitazone; Hypertension DiabetesⅡ
基于84个网页-相关网页
Pioglitazone Hydrochloride 吡格列酮 ; 格列酮 ; 盐酸匹格列酮
Pioglitazone Hydrochloride Tablets 盐酸吡格列酮片 ; 吡格列酮片 ; 盐酸吡格列酮胶囊 ; 注射用炎琥宁
Pioglitazone HCl 盐酸吡格列酮 ; 盐酸匹格列酮 ; 吡格列酮盐酸 ; 吡格列酮
Pioglitazone Hydrochloride Capsules 盐酸吡格列酮胶囊
Pioglitazone base 匹格列酮碱
Pioglitazone Hydrochloride Dispersible Tablets 盐酸吡格列酮分散片 ; 吡格列酮分散片 ; 万苏敏吡格列酮分散片
Pioglitazone Hydroc 吡格列酮片 ; 盐酸匹格列酮 ; 匹格列酮盐酸盐 ; 盐酸皮格列酮
Pioglitazone Hydrochloride Dispers 盐酸吡格列酮分散片
Pioglitazone Hydrochloride D 盐酸吡格列酮分散片
Methods A total of 45 wistar male rats were randomly distributed into 3 groups: control,IR and pioglitazone group.
方法45只W istar雄性大鼠随机分为对照组、胰岛素抵抗组和吡格列酮组。
参考来源 - 预防性应用吡格列酮改善胰岛素抵抗的脂肪内分泌机制Objective To investigate the apoptosis inducing effect of peroxisome proliferator activated receptor γ (PPARγ) agonist pioglitazone (PGZ) on leukemic HL-60 cells in vitro and its mechanisms of action.
目的 探讨过氧化物酶体增殖物激活受体γ(PPARγ)激动剂匹格列酮(PGZ)对白血病HL-60细胞的体外增殖抑制作用及其作用机制。
参考来源 - 过氧化物酶体增殖物激活受体γ激动剂对白血病HL·2,447,543篇论文数据,部分数据来源于NoteExpress
No difference between rosiglitazone and pioglitazone was apparent.
罗格列酮和匹格列酮间无明显差别。
It was financed in part by Takeda Pharmaceuticals, maker of pioglitazone.
它的部分经费由吡格列酮的制造商武田制药提供。
Beginning in 1999, rosiglitazone maleate and pioglitazone hydrochloride were approved for use.
从1999年开始,马来酸罗格列酮和盐酸匹格列酮被批准使用。
应用推荐